Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Up 6.25%
As of Wednesday, August 19, Aquestive Therapeutics, Inc.’s AQST share price has surged by 6.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. AQST
$4.65
0.15
3.34%
August 21, 2026 2:00:58 PM
EST
Volume: 1,198,911
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Commentary & Analysis
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Up 5.24%
As of Tuesday, August 11, Aquestive Therapeutics, Inc.’s AQST share price has surged by 5.24%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Aquestive Therapeutics, Inc.'s Q3 Earnings
Aquestive Therapeutics, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (AQST) missed or beat analyst's expectations.Jenna Brashear
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Up 13.58%
As of Monday, August 10, Aquestive Therapeutics, Inc.’s AQST share price has surged by 13.58%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Up 13.96%
As of Monday, August 10, Aquestive Therapeutics, Inc.’s AQST share price has surged by 13.96%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | AQST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $564.2 | $618.0 | 38% |
|
| Shares Out (Mil) | 125.0 | 44.8 | 67% |
|
| Institutional Ownership | 95.2% | 85.3% | 67% |
|
| Float (Mil) | 114.7 | 47.4 | 64% |
|
| Beta | 1.43 | 0.70 | 81% |
|
| Avg Daily Volume (000s) | 5,274 | 390 | 93% |
|
| Price Change (52-week) |
16.6% | 68.6% | 59% |
|
| Growth | AQST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.6%) | 6.7% | 16% |
|
| Net Income (5yr) | (8.5%) | (1.6%) | 30% |
|
| EPS (5yr) | 13.9% | 14.9% | 54 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 23.6% | (14.9%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.135) | ($0.450) | ($0.570) | |
| Month Ago EPS | ($0.120) | ($0.420) | ($0.450) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.120) | ($0.420) | ($0.450) | |
| Year/Year Chg | (26.2%) | (42.6%) | (68.8%) | |
| Financials | AQST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $291 | 21% |
|
| Net Income (TTM) (Mil) | ($78) | ($11) | 13% |
|
| EPS (TTM) | ($0.651) | ($0.700) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($45) | ($6) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $38 | $5 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $58 | $6 | 40% |
|
| Enterprise Value (Q1) (Mil) | $494 | $450 | 34% |
|
| Valuation | AQST | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AQST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 67.0% | 67.0% | 79% |
|
| Net Margin | (144.6%) | (2.3%) | 6% |
|
| ROA | (69.3%) | (22.4%) | 9% |
|
| ROE | 121.1% | (20.2%) | 97% |
|
| Liabilities to Assets | 142.8% | 32.2% | 98% |
|
| F-Score | 4 | 3 | 34% |
|
Aquestive Therapeutics, Inc. did not pass any screens on 8/20/2026.
